INTRODUCTION: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related death worldwide. It is traditionally difficult to cure, especially when discovered at later stages, making early diagnosis and intervention of paramount importance. HCC typically arises in the background of chronic liver disease and can have various morphologic appearances. One of the most difficult of these to recognize on early surveillance imaging is the infiltrative subtype, which can account for up to 13% of all HCC cases, and may be more closely associated with background hepatitis B infection. DISCUSSION: Certain imaging characteristics can provide vital clues, including differing signal intensity on the T1 and T2 sequences of magnetic resonance imaging (MRI) and the presence/appearance of portal vein thrombus. Owing to the diffuse and infiltrating properties of this tumor, surgical resection and transplantation are rarely if ever viable therapeutic options. Other forms of liver-directed therapy have been attempted with limited success, having minimal efficacy and high morbidity. To date, there is no data available to determine if the various HCC subtypes respond to systemic therapy differently, so this may be the most reasonable approach. Left untreated, observed patients commonly progress to hepatic failure fairly rapidly. CONCLUSION: Infiltrative HCC can be extremely subtle, and therefore difficult to detect, especially in the background of cirrhosis. Providers caring for patients with hepatitis, chronic liver disease, and cirrhosis must be extremely vigilant in the evaluation of surveillance imaging in order to potentially discover this HCC subtype as early as possible and initiate a multidisciplinary treatment plan.
INTRODUCTION:Hepatocellular carcinoma (HCC) is a leading cause of cancer-related death worldwide. It is traditionally difficult to cure, especially when discovered at later stages, making early diagnosis and intervention of paramount importance. HCC typically arises in the background of chronic liver disease and can have various morphologic appearances. One of the most difficult of these to recognize on early surveillance imaging is the infiltrative subtype, which can account for up to 13% of all HCC cases, and may be more closely associated with background hepatitis B infection. DISCUSSION: Certain imaging characteristics can provide vital clues, including differing signal intensity on the T1 and T2 sequences of magnetic resonance imaging (MRI) and the presence/appearance of portal vein thrombus. Owing to the diffuse and infiltrating properties of this tumor, surgical resection and transplantation are rarely if ever viable therapeutic options. Other forms of liver-directed therapy have been attempted with limited success, having minimal efficacy and high morbidity. To date, there is no data available to determine if the various HCC subtypes respond to systemic therapy differently, so this may be the most reasonable approach. Left untreated, observed patients commonly progress to hepatic failure fairly rapidly. CONCLUSION: Infiltrative HCC can be extremely subtle, and therefore difficult to detect, especially in the background of cirrhosis. Providers caring for patients with hepatitis, chronic liver disease, and cirrhosis must be extremely vigilant in the evaluation of surveillance imaging in order to potentially discover this HCC subtype as early as possible and initiate a multidisciplinary treatment plan.
Authors: Timothy M Pawlik; Ronnie T Poon; Eddie K Abdalla; Iwao Ikai; David M Nagorney; Jacques Belghiti; Reza Kianmanesh; Irene Oi-Lin Ng; Steven A Curley; Yoshio Yamaoka; Gregory Y Lauwers; Jean-Nicolas Vauthey Journal: Surgery Date: 2005-04 Impact factor: 3.982
Authors: Sun-Jung Myung; Jung-Hwan Yoon; Kang Mo Kim; Geum-Youn Gwak; Yoon Jun Kim; Ji-Won Yu; Jin Wook Chung; Hyo-Suk Lee Journal: Hepatogastroenterology Date: 2006 Mar-Apr
Authors: Timothy M Pawlik; Ronnie T Poon; Eddie K Abdalla; Daria Zorzi; Iwao Ikai; Steven A Curley; David M Nagorney; Jacques Belghiti; Irene Oi-Lin Ng; Yoshio Yamaoka; Gregory Y Lauwers; Jean-Nicolas Vauthey Journal: Arch Surg Date: 2005-05
Authors: Fabio Farinati; Dario Marino; Massimo De Giorgio; Anna Baldan; Maria Cantarini; Carmela Cursaro; Gianludovico Rapaccini; Paolo Del Poggio; Maria Anna Di Nolfo; Luisa Benvegnù; Marco Zoli; Franco Borzio; Mauro Bernardi; Franco Trevisani Journal: Am J Gastroenterol Date: 2006-03 Impact factor: 10.864
Authors: Peter J Kneuertz; Aram Demirjian; Amin Firoozmand; Celia Corona-Villalobos; Nikhil Bhagat; Joseph Herman; Andrew Cameron; Ahmet Gurakar; David Cosgrove; Michael A Choti; Jean-Francois H Geschwind; Ihab R Kamel; Timothy M Pawlik Journal: Ann Surg Oncol Date: 2012-04-03 Impact factor: 5.344
Authors: Eun Sun Jang; Jung-Hwan Yoon; Jin Wook Chung; Eun Ju Cho; Su Jong Yu; Jeong-Hoon Lee; Yoon Jun Kim; Hyo-Suk Lee; Chung Yong Kim Journal: J Cancer Res Clin Oncol Date: 2013-01-03 Impact factor: 4.553
Authors: Stephen L Chan; Frankie Mo; Philip J Johnson; Deyond Y W Siu; Michael H M Chan; Wan Y Lau; Paul B S Lai; Christopher W K Lam; Winnie Yeo; Simon C H Yu Journal: HPB (Oxford) Date: 2013-08-26 Impact factor: 3.647
Authors: J Zhang; M N Mavros; D Cosgrove; K Hirose; J M Herman; S Smallwood-Massey; I Kamel; A Gurakar; R Anders; A Cameron; J F H Geschwind; T M Pawlik Journal: Curr Oncol Date: 2013-04 Impact factor: 3.677
Authors: Rohan C Siriwardana; Chandika A H Liyanage; Bhagya Gunetilleke; Madunil A Niriella; Janaka de Silva; Anuradha S Dassanayake; Subani P Jayatunge Journal: Gastrointest Tumors Date: 2017-03-16